ZT006
ZT006 has been studied in 1 paper since 2026: 1 trial in people; 1 in the past year. The newest paper, Jun 5, 2026: “Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ZT006 Tablet, an Oral GLP-1 Receptor Agonist Peptide, in Healthy Participants, Participants with Overweight or Obesity: A Phase 1 Study”.
1 paper studies it1 findingUpdated
“In MAD, the mean weight loss on Day 43 in ZT006 groups was dose-dependent, and up to 11.7% in cohort 3 which was significantly greater than 4.8% in matched placebo group (p=0.0002).”
- 1 lab
- Human trial1
What did studies of ZT006 find?
1Studies of ZT006 measured 1 outcome; the most studied are body weight (1 study).
Body weight
downin humans1
1 study
Body weight
downin humans1
ZT006 decreases body weight in humans (11.7% vs 4.8% placebo (p=0.0002)).
“In MAD, the mean weight loss on Day 43 in ZT006 groups was dose-dependent, and up to 11.7% in cohort 3 which was significantly greater than 4.8% in matched placebo group (p=0.0002).”
Human trialin participants with overweight or obesity (MAD cohort 3)10/20/40 mg42 days
ADA Scientific Sessions 2026 abstract
Latest
1 paper in 12 monthsADA Scientific Sessions 2026 Abstract
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ZT006 Tablet, an Oral GLP-1 Receptor Agonist Peptide, in Healthy Participants, Participants with Overweight or Obesity: A Phase 1 Study
Randomized trial in peopleOverweight